Saturday - February 21, 2026
Calquence Plus Venetoclax Approved in the US as First All-Oral, Fixed-Duration Combination for Patients With Chronic Lymphocytic Leukemia in the 1st-Line Setting
February 21, 2026
WILMINGTON, Delaware, Feb. 21 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

CALQUENCE(R) plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

CALQUENCE plus venetoclax demonstrated statistically significant and clinically

meaningful improvement in progression-free survival vs. chemoimmunotherapy, with
. . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products